IP Library Granted Patent US 7,605,278
Granted Patent B2
US 7,605,278 · App. 10/522,696 · Granted Oct 20, 2009

Methods and compositions for converting taxane amides to paclitaxel or other taxanes

Assignee: Natural Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,605,278
App. No.
10/522,696
Granted
Oct 20, 2009
Kind
B2
Abstract

The invention relates to methods and compositions for converting taxane amides to paclitaxel or other taxanes. In one alternative embodiment, the present invention comprises; (i) selectively protecting at least one OH group of a taxane amide; (ii) contacting the taxane amide with a transition metal compound to reduce the amide; (iii) contacting the reduced amide with an agent capable of substantially removing the transition metal; (iv) contacting the reduced amide with a hydrolyzing amount of acid to form a taxane amine salt in solution; (v) adding a sufficient amount of solvent to solidify the amine salt; and (vi) converting the taxane amine salt into paclitaxel or other taxanes.

Claims (49)

1. A method for forming a taxane or precursor or analog thereof from a raw material, the raw material comprising a compound represented by the formula below:

wherein, R 2 is H, Ac or a protecting group;

R 3 is H, xylosyl or protecting group;

R 4 is H or protecting group;

R N is H or an alkyl group; and

X=deprotonated sulfuric acid or deprotonated sulfur containing acid; deprotonated nitric acid or other nitrogen containing acid; deprotonated carboxylic acid, except trifluoro acetic acid; deprotonated phosphoric acid or any phosphorus containing acid; deprotonated tartaric acid; deprotonated p-toluene sulfonic acid; or deprotonated picric acid; and

wherein said taxane or precursor or derivative thereof is in a solid, purified form;

the method comprising benzoylating the raw material with a benzoylation solution comprising a benzoylating agent and a buffer such that the pH of the benzoylation solution is about 4 to about 6.

2. The method of claim 1 , wherein the buffer comprises a phosphate buffer.

3. The method of claim 2 , wherein the phosphate buffer is of about pH 7.

4. The method of claim 1 , wherein R 2 is Ac and R 3 is H.

5. The method of claim 1 , wherein R 2 is H and R 3 is H.

6. The method of claim 1 , wherein R 2 is Ac and R 3 is xylosyl.

7. The method of claim 1 , wherein R 2 is H and R 3 is xylosyl.

8. The method of claim 1 , wherein R 2 , R 3 and R 4 is the protecting group selected from the group consisting of triethylsilyl, trimethylsilyl, trichloroethoxycarbonyl and ethoxyethyl ether.

9. The method of claim 1 , wherein R 3 and R 4 is a protecting group selected from the group consisting of triethylsilyl, triethylsilyl, trichloroethoxycarbonyl and ethoxyethyl ether.

10. The method of claim 1 , wherein R 3 and R 4 is trimethylsilyl.

11. The method of claim 1 , wherein R 4 is a protecting group selected from the group consisting of triethylsilyl, triethylsilyl, trichloroethoxycarbonyl and ethoxyethyl ether.

12. The method of claim 1 , wherein R 4 is trimethylsilyl.

13. A method of forming a taxane amine or salt comprising the steps of: (i) contacting a taxane imine according to the formula below with a protic solvent;

wherein, R 1 =alkyl, aryl, carbonyl or ether group;

R 2 =H, alkyl, aryl, ester, ether or protecting group;

R 3 =H, alkyl, aryl, ether, ester, xylosyl, or protecting group;

R 4 =H or protecting group;

(ii) contacting the taxane imine with an acid useful to effect hydrolysis of the imine; and

(iii) isolating a solid, purified taxane amine or salt by adding a solvent that is less polar than said protic solvent.

14. The method of claim 1 , wherein X is a deprotonated nitric acid or other nitrogen containing acids.

15. The method of claim 1 , wherein X is a deprotonated sulfur containing acid.

16. The method of claim 1 , wherein X is a deprotonated carboxcyclic acid, except trifluro acetic acid.

17. The method of claim 1 , wherein X is deprotonated phosphoric acid or any phosphorus containing acid.

18. The method of claim 1 , wherein X is deprotonated tartaric acid.

19. The method of claim 1 , wherein X is deprotonated perchloric acid.

20. The method of claim 1 , wherein X is deprotonated p-tolulene sulfonic acid.

21. The method of claim 1 , wherein X is a deprotonated picric acid.

22. The method of claim 1 , wherein the formed taxane is taxol A.

23. The method of claim 1 , wherein the formed taxane is taxol B.

24. The of claim 1 , wherein the formed taxane is taxol C.

25. The method of claim 1 , wherein the formed taxane is taxol D.

26. The method of claim 1 , wherein the formed taxane is taxol E.

27. The method of claim 1 , wherein the formed taxane is taxol F.

28. The method of claim 1 , wherein the formed taxane is taxol G.

29. The method of claim 1 , wherein the formed taxane is Docetaxel.

30. The method of claim 1 , wherein the formed taxane is Nonataxel.

31. The method of claim 1 , wherein the method further comprises contacting the benzoylation solution with an amine containing compound after the benzoylation reaction is complete.

32. The method of claim 31 , wherein the amine containing compound comprises a primary amine.

33. The method of claim 31 , wherein the amine containing compound comprises ammonium hydroxide.

34. The method of claim 31 , wherein the method further comprises isolating an organic layer and washing the organic layer with a composition comprising an amine containing compound.

35. The method of claim 13 , wherein the solvent used in step (iii) is selected from the group consisting of methyl tert-butyl ether, dichioromethane, heptane, hexane, toluene, and trifluorotoluene.

36. The method of claim 13 , wherein the acid used in step (ii) is selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, tartaric acid, p-toluene sulfonic acid, picric acid, and combinations thereof.

Assignments (8)
CHANGE OF NAME Recorded Jan 14, 2010
From: PHYTON, INC.
To: PHYTON HOLDINGS, LLC
Reel/Frame 023787/0470 →
CHANGE OF NAME Recorded Jan 14, 2010
From: PHYTON, INC.
To: PHYTON HOLDINGS, LLC
Reel/Frame 023786/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2010
From: NATURAL PHARMA CANADA, ULC; NATURAL PHARMACEUTICALS, INC.
To: PHYTON, INC.
Reel/Frame 023768/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2010
From: NATURAL PHARMA CANADA, ULC; NATURAL PHARMACEUTICALS, INC.
To: PHYTON, INC.
Reel/Frame 023768/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2010
From: NATURAL PHARMA CANADA, ULC; NATURAL PHARMACEUTICALS, INC.
To: PHYTON, INC.
Reel/Frame 023741/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2006
From: JUCHUM, JOHN S.; JOHNSON, JAMES H.; GALLAGHER, REX T.
To: NATURAL PHARMACEUTICALS, INC.
Reel/Frame 017697/0799 →
EMPLOYEE AGREEMENT WITH ASSIGNMENT OF INVENTIONS Recorded May 31, 2006
From: WANG, DASHENG
To: NATURAL PHARMACEUTICALS, INC.
Reel/Frame 017703/0655 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2006
From: WANG, DASHENG; JOHNSON, JAMES H.; GALLAGHER, REX T.
To: NATURAL PHARMACEUTICALS, INC.
Reel/Frame 017697/0667 →
Continuity (2)
Provisional Application 6040119100 · Aug 4, 2002
Related Publication 20080051589A1 · Feb 28, 2008